Evidence map›Paper›PMID 23088623›Full record

ArticleMolecular cancer2012

In vivo gene transfer targeting in pancreatic adenocarcinoma with cell surface antigens.

Marie Lafitte, Benoit Rousseau, Isabelle Moranvillier, Miguel Taillepierre, Evelyne Peuchant, Véronique Guyonnet-Dupérat, Aurélie Bedel, Pierre Dubus, Hubert de Verneuil, François Moreau-Gaudry and 1 more

Open access · goldAbstract read
In one paragraph

Article in Molecular cancer, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.0field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Article
  3. Cytotoxic CD8British journal of cancer · 2021
    Review
  4. In VivoInternational journal of molecular sciences · 2019
    Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Frontiers in Suicide Gene Therapy of Cancer.Journal of genetic syndromes & gene therapy · 2012
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Marie LafitteINSERM U1035, Bordeaux, France.
Benoit Rousseau
Isabelle Moranvillier
Miguel Taillepierre
Evelyne Peuchant
Véronique Guyonnet-Dupérat
Aurélie Bedel
Pierre Dubus
Hubert de Verneuil
François Moreau-Gaudry
Sandrine Dabernat
Université de Bordeaux · FRBordeaux Population Health · FRInserm · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPancreatic ductal adenocarcinoma is a deadly malignancy resistant to current therapies. It is critical to test new strategies, including tumor-targeted delivery of therapeutic agents. This study tested the possibility to target the transfer of a suicide gene in tumor cells using an oncotropic lentiviral vector.

resultsThree cell surface markers were evaluated to target the transduction of cells by lentiviruses pseudotyped with a modified glycoprotein from Sindbis virus. Only Mucin-4 and the Claudin-18 proteins were found efficient for targeted lentivirus transductions in vitro. In subcutaneous xenografts of human pancreatic cancer cells models, Claudin-18 failed to achieve efficient gene transfer but Mucin-4 was found very potent. Human pancreatic tumor cells were modified to express a fluorescent protein detectable in live animals by bioimaging, to perform a direct non invasive and costless follow up of the tumor growth. Targeted gene transfer of a bicistronic transgene bearing a luciferase gene and the herpes simplex virus thymidine kinase gene into orthotopic grafts was carried out with Mucin-4 oncotropic lentiviruses. By contrast to the broad tropism VSV-G carrying lentivirus, this oncotropic lentivirus was found to transduce specifically tumor cells, sparing normal pancreatic cells in vivo. Transduced cells disappeared after ganciclovir treatment while the orthotopic tumor growth was slowed down.

conclusionThis work considered for the first time three aspect of pancreatic adenocarcinoma targeted therapy. First, lentiviral transduction of human pancreatic tumor cells was possible when cells were grafted orthotopically. Second, we used a system targeting the tumor cells with cell surface antigens and sparing the normal cells. Finally, the TK/GCV anticancer system showed promising results in vivo. Importantly, the approach presented here appeared to be a safer, much more specific and an as efficient way to perform gene delivery in pancreatic tumors, in comparison with a broad tropism lentivirus. This study will be useful in future designing of targeted therapies for pancreatic cancer.

Indexed as

Gene Transfer TechniquesAnimalsAntigens, SurfaceCarcinoma, Pancreatic DuctalCell Line, TumorClaudinsDrug Delivery SystemsGanciclovirGene TargetingGenetic TherapyGreen Fluorescent ProteinsHumansLentivirusLuciferasesMiceMice, SCIDAntigens, SurfaceClaudinsCLDN18 protein, humanGanciclovirGreen Fluorescent ProteinsLuciferasesMucin-4Thymidine KinaseViral Proteins

Identifiers

PMID23088623
PMCPMC3546072
OpenAlexW2099063881

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.